GHSI Guardion Health Sciences, Inc. Stock Quote

GHSI [NASD]

Healthcare | Drug Manufacturers - Specialty & Generic | USA

Index	-	P/E	-	EPS (ttm)	-0.12	Insider Own	1.80%	Shs Outstand	88.32M	Perf Week	-39.81%
Market Cap	421.59M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	78.14M	Perf Month	-38.24%
Income	-9.30M	PEG	-	EPS next Q	-	Inst Own	4.10%	Short Float	6.23%	Perf Quarter	78.71%
Sales	1.90M	P/S	221.89	EPS this Y	22.50%	Inst Trans	-0.84%	Short Ratio	0.85	Perf Half Y	49.73%
Book/sh	0.12	P/B	23.50	EPS next Y	-	ROA	-68.10%	Target Price	-	Perf Year	14.63%
Cash/sh	0.07	P/C	43.02	EPS next 5Y	-	ROE	-75.30%	52W Range	0.99 - 8.40	Perf YTD	13.25%
Dividend	-	P/FCF	-	EPS past 5Y	-40.90%	ROI	-87.50%	52W High	-69.40%	Beta	-
Dividend %	-	Quick Ratio	8.70	Sales past 5Y	40.60%	Gross Margin	-	52W Low	159.60%	ATR	0.81
Employees	94	Current Ratio	9.80	Sales Q/Q	50.00%	Oper. Margin	-	RSI (14)	33.11	Volatility	19.51% 16.51%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	63.30%	Profit Margin	-	Rel Volume	0.55	Prev Close	2.82
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	5.73M	Price	2.57
Recom	-	SMA20	-50.09%	SMA50	-39.72%	SMA200	1.77%	Volume	3,163,428	Change	-8.87%

Feb-26-21 08:57AM	Guardion Health stock tumbles after reverse stock split announcement MarketWatch -27.36%
08:00AM	Guardion Health Sciences Announces 1-for-6 Reverse Stock Split Effective Pre-Market Opening on Monday, March 1, 2021 GlobeNewswire
Jan-28-21 04:15PM	Malaysias Ho Wah Genting Berhad Advises Guardion Health Sciences That It Has received Regulatory Product Registration Approval for Second Immune Support Dietary Supplement Designed and Produced by Guardion Health Sciences GlobeNewswire +16.48%
Jan-27-21 08:30AM	Nasdaq Grants Guardion Health Sciences an Extension to March 15, 2021 to Regain Compliance with the $1.00 Minimum Bid Price Rule GlobeNewswire
Jan-07-21 01:46AM	Should Guardion Health Sciences (NASDAQ:GHSI) Be Disappointed With Their 94% Profit? Simply Wall St. +6.19%
Dec-28-20 04:20PM	Guardion Health Sciences Appoints Seasoned Nutritional Products Industry Leader Bret Scholtes as President and Chief Executive Officer GlobeNewswire -8.36%
Dec-16-20 08:00AM	Guardion Health Sciences Announces Development of New Vision/Energy Support Drink EPIQ-V GlobeNewswire
Nov-12-20 04:05PM	Guardion Health Sciences Announces Financial Results for the Three Months and Nine Months Ended September 30, 2020 GlobeNewswire -6.72%
Oct-28-20 08:30AM	Guardion Health Sciences Announces Newly-Published Data Demonstrating Superior Visual Function and Macular Carotenoid Changes Using Guardions Proprietary Lumega-Z® Formulation Compared to AREDS-2 Formulation GlobeNewswire
Oct-27-20 08:30AM	Guardion Provides Answers to Frequently Asked Questions Regarding the Reasons for Approving the Reverse Stock Split Proposal at Upcoming 2020 Annual Stockholders Meeting GlobeNewswire -16.72%
Oct-26-20 08:00AM	Guardion Health Sciences Announces Investigator-Initiated Clinical Trial of Lumega-Z GlobeNewswire +10.40%
Oct-05-20 09:15AM	We Think Guardion Health Sciences (NASDAQ:GHSI) Needs To Drive Business Growth Carefully Simply Wall St.
08:30AM	Guardion Provides Update on Strategy, Business Plans and Initiatives GlobeNewswire
Sep-11-20 05:20PM	Guardion Announces Virtual Annual Meeting of Stockholders GlobeNewswire -8.09%
Aug-27-20 08:30AM	Guardion Health Sciences Product Licensee Receives Registration Approval in Malaysia for Immune Support Supplement GlobeNewswire
Aug-12-20 04:05PM	Guardion Health Sciences Reports Results of Operations for Quarter Ended June 30, 2020 GlobeNewswire
Aug-06-20 04:05PM	Guardion Health Sciences to Report Second Quarter 2020 Financial Results on August 12, 2020 GlobeNewswire
Jul-21-20 08:30AM	Guardion Health Sciences Adds Experienced Vice President and Chief Financial Officer to Executive Management Team GlobeNewswire
Jul-15-20 09:00AM	Guardion Subsidiary VectorVision Receives Approval from Korean Intellectual Property Office for CSV-2000 Trademark GlobeNewswire
Jul-08-20 08:45AM	Guardion Health Sciences Announces Submission of Patent Application for Treatment of Certain Underlying Conditions Related to Eye Disease GlobeNewswire
Jun-30-20 05:00AM	Guardion Health Sciences Completes Delivery of $875,000 Order to Malaysian Corporate Customer GlobeNewswire
Jun-15-20 04:20PM	Guardion Health Sciences Names Dr. David Evans as Interim President and Interim Chief Executive Officer GlobeNewswire +12.93%
May-14-20 07:00AM	Guardion Health Sciences Reports First Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire -6.83%
May-12-20 07:05AM	Lumega-Z® Demonstrates Superiority in a Head-to-Head Study Showing Better Bioavailability of Carotenoids and Restoring Macular Pigment Density GlobeNewswire
Apr-15-20 09:05AM	Guardion Health Sciences to Present at the April 2020 Virtual Investor Summit GlobeNewswire -11.16%
Apr-14-20 11:00AM	Guardion Health Sciences Announces Launch of acuMMUNE: An Immuno-Supportive/Anti-Oxidant Complex GlobeNewswire
Apr-01-20 07:00AM	Guardion Health Sciences Receives Initial Order from Malaysian Company for Exclusive Immuno-Supportive Formula GlobeNewswire -6.62%
Mar-30-20 09:00AM	Guardion Health Sciences Reports 2019 Year End Results and Provides Corporate Update and Overview GlobeNewswire -7.09%
Mar-19-20 12:05PM	Guardion Health Sciences Granted 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule GlobeNewswire
Mar-06-20 08:05AM	Guardion Health Sciences Receives $3.5 Million from Exercise of Warrants GlobeNewswire
Feb-26-20 07:00AM	Guardion Health Sciences Selected by Malaysian Listed Company to Develop an Immuno-Supportive Formula GlobeNewswire
Feb-06-20 07:00AM	Guardion® Announces Development of Unique Immuno-Supportive Complex Targeting Upper Respiratory Tract Infections GlobeNewswire +13.93%
Jan-07-20 11:02AM	Guardion® Appoints Experienced Executive to Lead Development and Expansion of Recently-Acquired NutriGuard Business Line GlobeNewswire -8.11%
Nov-14-19 07:00AM	Guardion Health Sciences, Inc. Reports Results for the Three and Nine Months Ended September 30, 2019 GlobeNewswire -8.52%
Oct-30-19 12:33PM	Guardion Health Sciences Closes $8.4 Million Underwritten Public Offering GlobeNewswire
Oct-28-19 09:21AM	Guardion Health Sciences Announces Pricing of $8.4 Million Underwritten Public Offering GlobeNewswire -34.80%
Oct-23-19 07:00AM	Guardion® Receives approval from USPTO for expanded claims for its Proprietary Medical Device, the MAPCAT SF GlobeNewswire
Oct-17-19 10:40AM	Here's Why We're A Bit Worried About Guardion Health Sciences's (NASDAQ:GHSI) Cash Burn Situation Simply Wall St.
Oct-10-19 10:30AM	Guardion® Announces Statistically Significant Blood Assay Study Results GlobeNewswire +5.10%
Sep-23-19 10:30AM	Guardion Health Sciences Acquires the NutriGuard Brand of Products GlobeNewswire +20.13%
Sep-03-19 02:08PM	Best & worst performing IPOs in 2019 Yahoo Finance Video
07:00AM	Guardion Launches VectorVision CSV-2000 Standardized Contrast Sensitivity Test GlobeNewswire
Aug-15-19 04:05PM	Guardion Health Sciences Closes $5.8 Million Underwritten Public Offering GlobeNewswire
08:35AM	Guardion Health Sciences Announces an Increase in the Pricing of its Previously Announced Underwritten Public Offering GlobeNewswire
Aug-13-19 09:00AM	Guardion Health Sciences Announces Pricing of $5.2 Million Underwritten Public Offering GlobeNewswire -59.66%
Aug-12-19 08:40AM	Guardion Health Sciences Reports June 30, 2019 Interim Results of Operations GlobeNewswire -8.49%
Aug-06-19 07:00AM	Foundation Fighting Blindness selects Guardions VectorVision CSV-1000 Diagnostic Instrument for Use in Large-Scale Multi-Center Clinical Trial GlobeNewswire
Jul-19-19 02:47PM	What Type Of Shareholder Owns Guardion Health Sciences, Inc.'s (NASDAQ:GHSI)? Simply Wall St.
Jul-17-19 07:00AM	Guardions Proprietary Medical Device, the MapcatSF®, Receives Patent from the Hong Kong Patents Registry GlobeNewswire +93.75%
Jun-20-19 07:00AM	Guardions Proprietary Medical Device, the MapcatSF®, Receives Patent from the European Union GlobeNewswire +7.23%
Jun-04-19 07:00AM	Guardion Launches Second Ocular Health Formula GlaucoCetin GlobeNewswire +24.84%
May-09-19 10:14AM	Guardions Lumega-Z Formula Associated with Substantial Clinical Improvement in Patients Contrast Sensitivity Visual Function (CSF) vs AREDS 2 GlobeNewswire
May-07-19 07:00AM	Guardion's Lumega-Z Formula Associated with Improved Vision in Patients with Severe Glaucoma GlobeNewswire
May-01-19 07:00AM	Guardion Health Sciences, Inc. Receives Official Trademark Registrations in China GlobeNewswire +6.36%
Apr-17-19 09:01AM	Results of Lumega-Z Data to be Presented at ARVO GlobeNewswire -12.00%
Apr-11-19 09:18AM	WallachBeth Capital Announces Completion of the $5 Million IPO for Guardion Health Services PR Newswire
Apr-09-19 12:20PM	Guardion Health Sciences, Inc. Announces Closing of Initial Public Offering GlobeNewswire -7.04%
Apr-05-19 12:49PM	Guardion Health Sciences, Inc. Announces Pricing of Initial Public Offering Business Wire

Guardion Health Sciences, Inc., together with its subsidiaries, operates as a specialty health sciences company in the United States. It operates in two segments, Medical Foods and Medical Devices. The Medical Foods segment offers Lumega-Z, a medical food that replenishes and restores the macular protective pigment; and GlaucoCetin, a vision-specific medical food to support and protect the mitochondrial function of optic nerve cells, as well as improve blood flow in the ophthalmic artery in patients with glaucoma. The Medical Devices segment offers VectorVision, which develops, manufactures, and sells equipment and supplies for standardized vision testing for use by eye doctors in clinical trials, real-world vision evaluation, and industrial vision testing; CSV-1000, an instrument for contrast sensitivity, glare sensitivity, low contrast acuity, and early treatment diabetic retinopathy; CSV-2000, a digital standardized contrast sensitivity testing device; and MapcatSF, a medical device that measures the macular pigment optical density. The company distributes its products through sales force, as well as through its guardionhealth.com Website. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in San Diego, California.

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience